Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with α-fetoprotein and protein induced by vitamin K absence or antagonist-II

Liver International

Volumn 26, Issue 7, 2006, Pages 789-795

  Yano, Yoichi ^a   Yamashita, Fumihiko ^a   Kuwaki, Kotaro ^a   Fukumori, Kazuta ^a   Kato, Osamu ^a   Yamamoto, Hiroshi ^a   Ando, Eiji ^b   Tanaka, Masatoshi ^b   Sata, Michio ^b  

^a Saga Social Insurance Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

fetoprotein (AFP); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Protein induced by vitamin K absence or antagonist II (PIVKA II)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ANTIVITAMIN K; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; RISK FACTOR; THROMBOCYTE COUNT; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746772985     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01310.x     Document Type: Article

References (23)

1. Bosch F X, Ribes J, Diaz M, et al. Primary liver cancer: World wide incidence and trends. Gastroenterology 2004; 127: S5-16.
2. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 2004; 127: S17-26.
3. Zaman S N, Melia W M, Johnson R D, et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients. Lancet 1985; i: 1357-60.
4. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver diseases. N Engl J Med 1993; 328: 1797-801.
5. Johnson P J, Melia W M, Palmer M K, et al. Relationship between serum alpha-fetoprotein, cirrhosis and survival in hepatocellular carcinoma. Br J Cancer 1981; 44: 502-5.
6. Stuart K E, Anand A J, Jenkins R L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217-22.
7. Shimada M, Takenaka K, Fujiwara Y, et al. Des-γ-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996; 78: 2094-100.
8. Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein. Cancer 2000; 88: 1557-64.
9. Okuda H, Nakanishi T, Takatsu K, et al. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α-fetoprotein alone and those seropositive for des-γ-carboxy prothrombin alone. J Gastroenterol Hepatol 2001; 16: 1290-6.
10. Dohmen K, Shigematsu H, Irie K, et al. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of α-fetoprotein and des-γ-carboxy prothrombin. Hepatogastroenterology 2003; 50: 2072-8.
11. Ohhira M, Ohtake T, Saito H, et al. Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma. Alcohol Clin Exp Res 1999; 23: 67S-70S.
12. Tang W, Miki K, Kokudo N, et al. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 2003; 22:969-75.
13. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellularcarcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
14. Anzola M. Hepatocellular carcinoma: Role of hepatitis B and hepatitis C viruses in hepatocarcinogenesis. J Viral Hepat 2004; 11: 383-93.
15. Liang T J, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127: S62-71.
16. Tanaka K, Sakai H, Hashizume M, et al. A long-term follow-up study of risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 1998; 89: 1241-50.
17. Kubo S, Hirohashi K, Tanaka H, et al. Risk factor for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 2000; 24: 1559-65.
18. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127: S35-50.
19. Heathcote E J. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S294-302.
20. Nakagawa T, Seki T, Shiro T, et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and α-fetoprotein in hepatocellular carcinoma. Int J Oncol 1999; 14: 281-6.
21. Koike Y, Shiratori Y, Sato S, et al. Des-gamma- carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
22. Child C G Turcotte J G. Surgery and portal hypertension. In: Child C G, ed. The Liver and Portal Hypertension. Philadelphia: WB Saunders, 1964; 49-51.
23. Hermanek P, Sobin L H, (eds). TNM Classification of Malignant Tumors, 4th edn. UICC. Berlin: Springer Verlag, 1987.